Welcome to our dedicated page for Regenxbio SEC filings (Ticker: RGNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Regenxbio’s gene-therapy disclosures can span hundreds of pages filled with trial protocols, FDA correspondence, and complex licensing terms. Finding the cash runway buried in a 10-K or spotting an ABBV-RGX-314 milestone in an 8-K shouldn’t take your entire day.
Our platform solves that problem. Stock Titan’s AI reads every Regenxbio quarterly earnings report 10-Q filing, Regenxbio annual report 10-K simplified, and Regenxbio 8-K material events explained the moment they hit EDGAR. It then delivers plain-English summaries, red-flags key risk factors, and links the numbers to trial timelines—perfect for understanding Regenxbio SEC documents with AI rather than parsing biotech jargon yourself.
Need to monitor insider sentiment? Real-time alerts surface Regenxbio Form 4 insider transactions, letting you gauge executive confidence before the market reacts. Curious about compensation? The latest Regenxbio proxy statement executive compensation is broken down line by line. Whether you’re tracking Regenxbio insider trading Form 4 transactions, reviewing manufacturing disclosures, or running a quick Regenxbio earnings report filing analysis, every filing type—10-K, 10-Q, 8-K, S-3, DEF 14A—is indexed, searchable, and annotated. Skip the PDFs; get the insights that matter.
REGENXBIO Inc. filed a shelf registration statement allowing it to offer and sell up to $300,000,000 of securities over time. The mix may include common stock, preferred stock, warrants, debt securities, rights and units, in one or more offerings, with final terms set in future prospectus supplements. Any securities can be sold directly, or through underwriters, dealers or agents.
REGENXBIO, a gene therapy-focused biotechnology company, plans to use net proceeds for general corporate purposes, including financing clinical trials, capital expenditures, working capital, pipeline development, expanding commercial capabilities, general and administrative expenses, potential debt repayment and possible acquisitions or investments. Its common stock trades on the Nasdaq Global Select Market under the symbol RGNX and closed at $13.45 on November 25, 2025. As of September 30, 2025, 50,618,692 shares of common stock were outstanding.
REGENXBIO Inc. (RGNX) furnished quarterly results. The company submitted an 8‑K announcing it issued a press release covering results of operations and financial condition for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and incorporated by reference therein.
The information under Item 2.02 and Exhibit 99.1 is furnished, not filed, under the Exchange Act. REGENXBIO’s common stock trades on the Nasdaq Global Select Market under the symbol RGNX.
REGENXBIO Inc. reported Q3 2025 results. Total revenue was $29.7 million, driven by $23.6 million of license and royalty revenue and $6.1 million of service revenue. For the nine months, revenue reached $140.1 million.
The company posted a Q3 net loss of $61.9 million and a basic and diluted net loss per share of $1.20. Interest expense rose to $13.2 million in the quarter, reflecting royalty financing activity. Operating expenses were $82.1 million in Q3, led by $56.1 million in research and development and $20.3 million in general and administrative costs.
Cash, cash equivalents and marketable securities totaled $302.0 million as of September 30, 2025. Royalty monetization liabilities increased to $191.6 million, including a new 2025 Royalty Bond initially funded with $150.0 million (net proceeds $144.5 million). Deferred revenue rose to $34.4 million current and non-current combined, aligned with recent collaboration activity and the new presentation separating service revenue. Shares outstanding were 50,623,086 as of October 31, 2025.
Simpson Curran, who is listed as both Chief Executive Officer and a Director of REGENXBIO Inc. (RGNX), reported an open-market sale of company common stock under a pre-existing trading plan. On
Following this reported transaction the reporting person beneficially owned 216,162 shares. The Form 4 was signed via attorney-in-fact on
REGENXBIO, Inc. (RGNX) filed a Form 144 notifying the proposed sale of 20,811 common shares with an aggregate market value of
The filing discloses recent Rule 10b5-1 sales by the same person: 7,624 shares sold on
Simpson Curran, serving as Chief Executive Officer and a director of REGENXBIO Inc. (RGNX), reported a sale of 7,624 shares of the issuer's common stock on 09/29/2025. The sale was effected under a Rule 10b5-1 trading plan and executed in multiple trades at prices ranging from $10.00 to $10.08, with a weighted average sale price of $10.03. Following the reported transaction, the reporting person beneficially owned 236,973 shares, held directly. The Form 4 was signed by an attorney-in-fact, Patrick J. Christmas, on 10/01/2025. No derivative transactions or other securities classes were reported in this filing.
REGENXBIO Inc. (RGNX) filed a Form 144 notifying the proposed sale of 15,358 shares of its common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $151,890.62 and an approximate planned sale date of 09/10/2025 on NASDAQ.
The shares were acquired as Restricted Stock Units from the issuer on 01/01/2023 and total outstanding shares are reported as 50,514,216, making the planned sale approximately 0.03% of outstanding stock. The filing affirms the signer does not possess undisclosed material adverse information and indicates no securities were sold in the past three months by the reporting person.
Craig Malzahn, Chief Technology Officer of REGENXBIO Inc. (RGNX), reported a non-derivative transaction dated 09/01/2025 in which 234 shares of common stock were disposed at a price of $8.93 per share. After the transaction he beneficially owned 17,585 shares directly. The filing states the 234 shares were withheld to pay taxes upon the vesting of restricted stock units originally granted on September 1, 2022, with the withholding amount calculated using the issuer's closing stock price on August 29, 2025. The form was signed via attorney-in-fact on 09/03/2025.
Chan Mitchell, the Chief Financial Officer of REGENXBIO Inc. (RGNX), reported a non-derivative disposition on 09/01/2025. The filing shows 4,901 shares of common stock were withheld to satisfy taxes upon the vesting of restricted stock units originally granted on September 16, 2024, using a withholding price of $8.93 (based on the closing price on August 29, 2025). After the withholding, the reporting person beneficially owns 53,968 shares directly. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 09/03/2025.
FAQ
What is the current stock price of Regenxbio (RGNX)?
What is the market cap of Regenxbio (RGNX)?
